進行がんを患う日本人参加者を対象としたオララツマブの研究

基本情報

NCT ID

NCT02377752

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

25

治験依頼者名

Eli Lilly and Company

概要

This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate safety and side effects of olaratumab in combination with doxorubicin in Japanese participants with a group of rare cancers (advanced solid tumors, especially advanced soft tissue sarcoma \[STS\].) The main purpose of Part B is to evaluate how much olaratumab gets into the blood stream of Japanese participants with advanced solid tumors and how long it takes the body to get rid of it.

対象疾患

介入

依頼者（Sponsor）